Abstract #3003

Hyperpolarized 13C MRSI of pyruvate and urea can detect immunomodulatory responses to dimethyl fumarate therapy in a model of multiple sclerosis

Caroline Guglielmetti^1,2, Christian Cordano³, Chloe Najac⁴, Ari Green³, and Myriam M Chaumeil^1,2

¹Department of Physical Therapy and Rehabilitation Science, University of California San Francisco, San Francisco, CA, United States, ²Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States, ³Department of Neurology, University of California San Francisco, San Francisco, CA, United States, ⁴Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden University Medical Center, Leiden, Netherlands

We used hyperpolarized ¹³C magnetic resonance spectroscopic imaging (HP ¹³C MRSI) and T₁-MRI to assess dimethyl fumarate (DMF) response in a model of multiple sclerosis (MS). Gadolinium-enhanced T₁-MRI showed blood-brain-barrier breakdown, regardless of DMF treatment. In contrast, DMF therapy prevented an increase compared to untreated MS animals in HP ¹³C lactate, HP ¹³C lactate-to-pyruvate and HP ¹³C lactate-to-(pyruvate/urea) ratios. HP ¹³C MRSI findings were further correlated to pyruvate dehydrogenase activity and pro-inflammatory macrophages. Altogether, we demonstrated that HP ¹³C MRSI has potential to monitor the effect of immunomodulatory therapies within the central nervous system.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here